Moderna's $140 million investment in Norwood, Massachusetts, aims to complete its U.S. manufacturing loop, enhancing ...

Learn how outdated or incomplete insights turn every decision into a high-stakes gamble that cost brands money, momentum, and ...

David Edelman, Founder & CEO of Thrivable, provides an unflinching look at why today’s most relied-upon tools, including ...

This series kicks off by introducing David Edelman, Founder & CEO of Thrivable, who joins Pharmaceutical Executive to discuss ...

Discover how AI-powered patient intelligence is ushering in a new era of pharma leadership defined by clarity, speed, and ...

Understand how real-time patient intelligence transforms leadership conversations from speculation and opinion battles into ...

This episode acts as a peek inside the modern pharma boardroom, where leaders are expected to defend billion-dollar brands ...

Just a few weeks after the company announced licensing agreements with Empirico and Syndivia, GSK announced a strategic ...

Alkermes’ $1.50 CVR price is contingent upon approval for Avadel’s leading treatment candidate for idiopathic hypersomnia in ...

Craig Ackerman, partner in the Alexander Group and lead of its medical device practice, discusses how AI is being used and ...

AbbVie and Genmab have received FDA approval for Epkinly as a treatment option for patients with relapsed or refractory follicular lymphoma. The decision adds a new targeted immunotherapy to the ...

The first wave of Commissioner’s National Priority Vouchers signals a fundamental shift in FDA competitiveness, rewarding companies that pair breakthrough science with affordability commitments, ...